Cytosorbents Corp (NASDAQ:CTSO) – Stock analysts at Dawson James raised their FY2021 earnings per share (EPS) estimates for Cytosorbents in a research report issued to clients and investors on Monday, August 12th. Dawson James analyst J. Kolbert now expects that the medical research company will post earnings per share of $0.46 for the year, up from their previous forecast of $0.43. Dawson James also issued estimates for Cytosorbents’ FY2022 earnings at $1.19 EPS and FY2023 earnings at $2.24 EPS.
Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. The business had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.53 million. Cytosorbents had a negative return on equity of 105.97% and a negative net margin of 72.43%.
CTSO opened at $4.77 on Wednesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 3.21 and a quick ratio of 3.00. The business has a 50 day simple moving average of $6.65 and a 200-day simple moving average of $7.13. The stock has a market capitalization of $173.47 million, a P/E ratio of -8.52 and a beta of 1.50. Cytosorbents has a 12 month low of $3.68 and a 12 month high of $14.95.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTSO. D. E. Shaw & Co. Inc. bought a new stake in shares of Cytosorbents in the second quarter valued at about $164,000. Vanguard Group Inc. raised its position in Cytosorbents by 0.5% in the second quarter. Vanguard Group Inc. now owns 1,375,707 shares of the medical research company’s stock worth $9,094,000 after purchasing an additional 6,698 shares in the last quarter. BlackRock Inc. raised its position in Cytosorbents by 1.1% in the second quarter. BlackRock Inc. now owns 2,008,123 shares of the medical research company’s stock worth $13,274,000 after purchasing an additional 21,791 shares in the last quarter. Northern Trust Corp raised its position in Cytosorbents by 1.7% in the second quarter. Northern Trust Corp now owns 354,447 shares of the medical research company’s stock worth $2,343,000 after purchasing an additional 5,852 shares in the last quarter. Finally, Sargent Investment Group LLC raised its position in Cytosorbents by 15.9% in the second quarter. Sargent Investment Group LLC now owns 333,910 shares of the medical research company’s stock worth $2,207,000 after purchasing an additional 45,840 shares in the last quarter. 26.35% of the stock is owned by hedge funds and other institutional investors.
Cytosorbents Company Profile
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Read More: Put Option
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.